ReviewInternational journal of molecular sciences2023
microRNAs (miRNAs) in Glioblastoma Multiforme (GBM)-Recent Literature Review.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Diagnostic and Prognostic Values of miRNAs in High-Grade Gliomas: A Systematic Review.F1000Research · 2024Pooled it
- Circulating miRNAs for glioblastoma monitoring: from biofluid to clinical decision.Molecular therapy. Oncology · 2026Review
- Molecular Engineering of Aptamers for Glioblastoma Therapy: From Simple Antagonists to AI-Driven Approaches, a Narrative Review.International journal of molecular sciences · 2026Review
- Human umbilical cord mesenchymal stem cells derived exosomes enhance the therapeutic efficacy of anti-miR-10b in glioblastoma.Scientific reports · 2026Article
- Research trends in microRNAs in glioma tumors: A data-driven exploration using a bibliometric approach.IBRO neuroscience reports · 2026Review
- Evolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers.Brain sciences · 2026Review
- Locoregional Delivery of miRNAs for Glioblastoma Treatment: A Systematic Review of Advances in Delivery Systems.Pharmaceutics · 2026Review
- Article
- Exercise-associated microRNA programs as candidate modulators and biomarkers in glioblastoma: a narrative review.Discover oncology · 2026Review
- MicroRNAs as diagnostic prognostic and therapeutic biomarkers in glioblastoma.Discover oncology · 2026Review
- Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens.Diagnostics (Basel, Switzerland) · 2026Article
- Invasiveness-related microRNA expression in glioma: associations with clinical outcomes, tumor burden, and health-related quality of life.Cancer cell international · 2026Article
- RNA therapeutic targeting of recalcitrant and rare cancers.Exploration of targeted anti-tumor therapy · 2026Review
- Sprouty in Tumors of the Nervous System.International journal of molecular sciences · 2025Review
- Recent advances in molecular mechanisms of microRNAs in pathogenesis and resistance of treatment in glioblastoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Translational role of molecular biomarkers in developing targeted therapies for central nervous system tumors.IBRO neuroscience reports · 2025Review
- MiR-205-5p downregulation and circ_100290 upregulation in glioblastoma patients are associated with tumor aggressiveness.Discover oncology · 2025Article
- Rapid early progression of glioblastoma: evaluation of a novel prognostic radiologic biomarker.Journal of neuro-oncology · 2025Article
- The role and therapeutic value of NUSAP1 in human cancers.Journal of translational medicine · 2025Review
- MSC-derived extracellular vesicles: Precision miRNA delivery for overcoming cancer therapy resistance.Regenerative therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme (GBM) is the most common, malignant, poorly promising primary brain tumor. GBM is characterized by an infiltrating growth nature, abundant vascularization, and a rapid and aggressive clinical course. For many years, the standard treatment of gliomas has invariably been surgical treatment supported by radio- and chemotherapy. Due to the location and significant resistance of gliomas to conventional therapies, the prognosis of glioblastoma patients is very poor and the cure rate is low. The search for new therapy targets and effective therapeutic tools for cancer treatment is a current challenge for medicine and science. microRNAs (miRNAs) play a key role in many cellular processes, such as growth, differentiation, cell division, apoptosis, and cell signaling. Their discovery was a breakthrough in the diagnosis and prognosis of many diseases. Understanding the structure of miRNAs may contribute to the understanding of the mechanisms of cellular regulation dependent on miRNA and the pathogenesis of diseases underlying these short non-coding RNAs, including glial brain tumors. This paper provides a detailed review of the latest reports on the relationship between changes in the expression of individual microRNAs and the formation and development of gliomas. The use of miRNAs in the treatment of this cancer is also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.